Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.

Much of the responsibility for ensuring safety is therefore delegated to the pump companies themselves (including companies that provide insulin infusion sets [IISs] and insulin products).

The insulin infusion pump market is expected to further boom in the future with projections suggesting a jump to $10.31 billion by 2029, riding a CAGR of 10.2%.